You just read:

Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After A Single Dose In Patients With Glaucoma

News provided by

Envisia Therapeutics

Oct 17, 2016, 08:15 ET